BC Week In Review | May 26, 2014
Clinical News

CLP-1001: Completed Phase IIb enrollment

Sorbent completed enrollment of 275 patients with signs and symptoms of fluid overload following a recent heart failure-related hospitalization in the double-blind, placebo-controlled, U.S. Phase IIb STEPWISE trial evaluating twice daily 15 g CLP-1001. The...
BC Week In Review | Apr 15, 2013
Clinical News

CLP-1001: Phase IIb started

Sorbent began the double-blind, placebo-controlled, U.S. Phase IIb STEPWISE trial to evaluate twice daily 15 g CLP-1001 in about 250 patients with signs and symptoms of fluid overload following a recent heart failure-related hospitalization. Last...
BC Week In Review | Jun 18, 2012
Clinical News

CLP-1001: Phase IIa data

A double-blind Phase IIa trial in 111 heart failure patients with CKD showed that CLP-1001 for 8 weeks significantly improved functional heart capacity as measured by the proportion of patients who achieved an improvement of...
BC Extra | Jul 1, 2011
Financial News

Sorbent raises $36M in expanded B round

Sorbent Therapeutics Inc. (Sunnyvale, Calif.) raised $36 million in a second tranche of a series B round, bringing the total raised in the round to $53 million. New investor Novartis Venture Funds led the tranche,...
BC Extra | Sep 10, 2010
Financial News

Sorbent raises $17 million

Sorbent Therapeutics Inc. (Sunnyvale, Calif.) raised $17 million in a series B round. New investor AgeChem Venture Fund joined existing investors CMEA Capital; Arch Venture Partners; Sofinnova Ventures; and Dow Chemical Co. (NYSE:DOW). Sorbent also...
Items per page:
1 - 5 of 5